drugset / Trial / NCT03654612
Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies
Phase 1/2
Unknown
30 enrolled
China International Medical Foundation
Chinese Society of Clinical Oncology · collab
NaSingle-groupOpen-labelTreatment
Summary
This open, single-arm, exploratory study looked at the efficacy and safety of apatinib in combination with S-1 as second-line treatment of advanced head and neck malignancies.
Timeline
- Start
- 2018-10-16
- Primary completion
- 2020-03-01
- Completion
- 2021-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | — |
| Subject | S-1 | Small molecule | 50 mg | — |